Neologics Bioscience | ApexOnco - Clinical Trials news and analysis

x

“I am very impressed - it has become my go-to platform”

Chief Business Officer

US public biotech company

Click here for more information

Trial results

31 January 2024

Novartis calls time on TIM-3 and HIF2α

The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.

Subscribe to Neologics Bioscience